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Glioblastoma (GBM) is the most common type of malignant brain tumor in adults.
We show here that small molecule 2-[(3,4-dihydroquinolin-1(2H)-yl)(p-tolyl)methyl]phenol
(THTMP), a potential anticancer agent, increases the human glioblastoma cell death.
Its mechanism of action and the interaction of selective signaling pathways remain
elusive. Three structurally related phenolic compounds were tested in multiple glioma
cell lines in which the potential activity of the compound, THTMP, was further validated
and characterized. Upon prolonged exposer to THTMP, all glioma cell lines undergo
p53 and cyclin-dependent kinase mediated cell death with the IC50 concentration of
26.5 and 75.4 µM in LN229 and Snb19, respectively. We found that THTMP strongly
inhibited cell growth in a dose and in time dependent manner. THTMP treatment led
to G1/S cell cycle arrest and apoptosis induction of glioma cell lines. Furthermore, we
identified 3,714 genes with significant changes at the transcriptional level in response
to THTMP. Further, a transcriptional analysis (RNA-seq) revealed that THTMP targeted
the p53 signaling pathway specific genes causing DNA damage and cell cycle arrest
at G1/S phase explained by the decrease of cyclin-dependent kinase 1, cyclin A2,
cyclin E1 and E2 in glioma cells. Consistently, THTMP induced the apoptosis by
regulating the expression of Bcl-2 family genes and reactive oxygen species while it also
changed the expression of several anti-apoptotic genes. These observations suggest
that THTMP exerts proliferation activity inhibition and pro-apoptosis effects in glioma
through affecting cell cycle arrest and intrinsic apoptosis signaling. Importantly, THTMP
has more potential at inhibiting GBM cell proliferation compared to TMZ, the current
chemotherapy treatment administered to GBM patients; thus, we propose that THTMP
may be an alternative therapeutic option for glioblastoma.
Keywords: phenol, anticancer, cytotoxicity, apoptosis induction, gene expression, cell cycle
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INTRODUCTION
Glioblastoma (GBM) is known as the most aggressive primary
brain tumor. Although different treatments have been combined
such as surgical operation, chemotherapy, or radiotherapy,
no standard treatment has been proven to be effective for
treating brain tumor. It is noted that patients with glioblastoma
have an average survival of 12–15 months. For chemotherapy,
temozolomide (TMZ) is one of the drugs accepted to be used
in combination with radiotherapy to treat brain tumor (Stupp
et al., 2005). However, some limitations related to use of
TMZ such as the over expression of O6-methylguanine-DNA
methyltransferase (MGMT) and/or lacking of a DNA repair
pathway in GBM cells (Hegi et al., 2005) still need to be addressed;
therefore, effective recurrence needs to be explored further.
A comprehensive understanding of the response of
glioblastomas to chemotherapy and detailed chemotherapy
resistance analysis of gliomas may help to identify effective
agents for the treatment of this disease. Currently, many
chemical compounds including sorafenib (Yang et al., 2010),
bevacizumab (Friedman et al., 2009), and kaempferol (Sharma
et al., 2007) have been studied for anti-glioma ability, especially
for inducing GBM growth arrest and apoptosis. In the past
few decades, many efforts have been made in understanding
chemotherapy-induced DNA damage response (DDR) such
as activation of checkpoint, repair and cell death pathways. It
is reported that GBM responds to DNA damage induced by
genotoxic drugs by activating DNA repair machinery (Erasimus
et al., 2016). Thereby, improving chemotherapy response should
be made to address this issue. Beside the DNA damage, targeting
cell cycle arrest and apoptosis also grasped the attention for GBM
treatment. In glioma cells, several key regulatory elements of
cell cycle and apoptosis alter the expression of cyclin-dependent
kinases such as Bcl-2 protein family, p53 protein, inhibitor of
apoptosis proteins (IAPs) or receptor tyrosine kinases like the
epidermal growth factor receptor (EGFR) and their down-stream
signaling cascade. Among these signaling pathways, p53 plays
an essential role in cellular responses to DNA damage and
regulation of cell cycle and apoptosis. It is well known that
p53 functions as a transcription factor for genes relevant for
the regulation of the cell cycle (e.g., p21) or apoptosis (e.g.,
BAX, BAK, PUMA, Bcl-2). Furthermore, p53 may also promote
apoptosis through transcription-independent mechanisms and
direct interactions with members of the Bcl-2 family of proteins
in the cytosol or mitochondria.
In the past decades, many advances have been made in
understanding the ability of phenolic compounds in acting
as effective chemopreventive agents especially throughout the
properties of inducing cell cycle arrest and apoptosis in
tumor cells (Wu et al., 2009). Several mechanisms were
studied explaining the effectiveness of these compounds as
chemopreventive agents for cancer treatment. These compounds
can suppress the overexpression of pro-oxidant enzymes
implicated in the development of cancer. They are also able to
inhibit the transcriptional factor activation, thus regulating target
genes correlated with cell survival, apoptosis and proliferation
(Wcislo et al., 2013). For instance, polyphenols have the ability
to modulate various targets of apoptosis pathways including the
expression of regulatory proteins, cytochrome c, activation of
caspase 9 and caspase 3 (Selvendiran et al., 2006), increase of
caspases-8 and t-Bid levels (Selvendiran et al., 2006), increase
of Bax and Bak expression (Selvendiran et al., 2006), down-
regulation of Bcl-2 and Bcl-XL expression, and modulation of
transcription factor NF-κB (Gong et al., 2003). In addition,
a study of resveratrol, a natural phenol, revealed the ability
to prevent or delay the onset of several types of cancers
because they can regulate multiple cellular processes associated
with carcinogenesis. In detail, this compound can inhibit cell
proliferation and induce apoptosis by dysregulating cell cycle
(Gali-Muhtasib et al., 2015), increasing caspase activity (Kim
et al., 2003), and decreasing Bcl-2 and Bcl-XL levels.
Alkylaminophenols, being Mannich bases, are a particular
kind of phenols (Roman, 2015). Although reported as precursors
of quinone methides (Weinert et al., 2006), which can
react with biomacromolecules (Thompson et al., 1993),
alkylaminophenol moiety is also found in some FDA-approved
drugs namely, amodiaquine, used for malaria treatment (Olliaro
et al., 1996) and in topotecan, a topoisomerase inhibitor
chemotherapeutic agent (Pommier, 2006). Previously, we
reported the potential anticancer activity as apoptosis inducer
of several alkylaminophenols on osteosarcoma cells, namely:
N-[2-hydroxy-5-nitrophenyl(4′-methylphenyl)methyl]indoline
(HNPMI) (Doan et al., 2016), 2-[(1,2,3,4-tetrahydroquinolin-
1-yl)(4-methoxyphenyl)methyl]phenol (THMPP) (Karjalainen
et al., 2017) and 2-[(3,4-dihydroquinolin-1(2H)-yl)(p-
tolyl)methyl]phenol (THTMP) (Neto et al., 2016). To our
knowledge, the anticancer activity of various phenolic derivatives
have been evaluated on several human cancer cell lines but the
effect as well as the in depth mechanism of phenols on brain
cancer are not well investigated. Motivated by the numerous
reports on the anticancer properties of phenolic compounds
and our previous studies on alkylaminophenols, we recently
examine the effect of HNPMI, THMPP, and THTMP on multiple
glioblastoma cell lines (1321N1, LN229, and Snb19). Several
in vitro preclinical assays were performed to indicate the
cytotoxicity of this derivative on GBM. Specifically, the ability
to kill GBM cells.
In spite of the multiple mechanisms have been proposed for
chemotherapeutic resistance in glioblastoma cells, the analysis
of molecular signaling events is still not comprehensive. To
date, advances in high-throughput sequencing methodology
have provided a large amount of information regarding gene
expression at the transcriptome level, as well as the underlying
molecular events in response to chemotherapeutic drugs. Hence,
the RNA-seq technique was used in this work to investigate
alkylaminophenol -responsive genes in GBM cells. Here, we
compared the gene expression profile of GMB cells between
an alkylaminophenol and temozolomide. After determining the
gene expression profile, we focused on the cell cycle arrest and
the apoptosis pathway activated by our alkylaminophenol and
investigated the significant of cell cycle genes as well as pro-
apoptosis and anti-apoptosis genes in gliomas chemotherapeutic
resistance. The cell cycle arrest was then validated by FUCCI
biosensor and the apoptosis induction validation was performed
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using Annexin V and PI double staining. Moreover, ROS
production and caspase 3/7 activation measurements were
conducted to reconfirm the involvement of apoptosis pathway
when the GBM cells were treated with phenolic derivatives.
MATERIALS AND METHODS
GBM Cell Lines and Chemical
Preparation
1321N1 is a human astrocytoma cell line isolated as a sub clone
of the cell line 1181N1 which in turn was isolated from the parent
line U-118 MG (one of a number of cell lines derived from
malignant gliomas). LN229 cell line was taken from a patient
with right frontal parieto-occipital glioblastoma. The cells exhibit
mutated p53 (TP53) and possible homozygous deletions in the
p16 and p14ARF tumor suppressor genes. Snb19 is a malignant
glioblastoma cell line initiated from the surgical resection of a
left parietooccipital glioblastoma multiforme tumor. This line has
been shown by DNA profiling studies to be a derivative of the
U-373 cell line.
Synthesis and spectral characterization of compounds HNPMI
(18), THMPP (19), and THTMP (20) were previously reported.
These compounds and TMZ (Sigma-Aldrich, United States)
were dissolved in dimethyl sulphoxide (DMSO, Sigma-Aldrich,
St. Louis, MO, United States) to obtain a stock of 100 mM,
from which, intermediate dilutions were prepared. The final
concentrations used were 100, 75, 50, 25, and 10 µM, in
the culture medium.
Cell Culture
The human glioma cell lines Snb19, LN229, and mouse
embryonal fibroblast (MEF) cell lines were cultured in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10% FBS,
0.1 mg/ml Streptomycin, 100 U/ml Penicillin, and 0.025 mg/ml
Amphotericin B. For 1321N1 cell line, the culture medium
was prepared as previously but it was supplemented with
2 mM sodium pyruvate. HEK293T cells were cultured in
DMEM supplemented with 10% FBS, 0.1 mg/ml Streptomycin,
100 U/ml Penicillin, 2 mM sodium pyruvate, and 0.025 mg/ml
Amphotericin B. The culture was maintained at 37◦C in
a humidified atmosphere containing 5% CO2. All of the
components for cell culture were purchased from Sigma-Aldrich,
St. Louis, MO, United States.
In vitro Cytotoxicity Assay
Cytotoxicity assay was performed to evaluate cell growth
inhibition of the three compounds HNPMI, THMPP, and
THTMP at 100 µM concentration on three glioblastoma cell
lines (1321N1, Snb19, and LN229). Cells were seeded with an
initial density of 1 × 105 cells/well in 12-well plates containing
appropriate medium for each cell line. When the cells reach
60–70% of confluence, the cells were then treated with the
three compounds at 100 µM and incubated for 24 h at culture
conditions. Treated cells were collected using centrifugation
at 3000 rpm for 10 min. Number of live and dead cells
were determined using trypan blue solution and Countess
II FL Automated Cell Counter (Thermo Fisher Scientific).
Inhibition percentage was calculated using the formula (1). In this
experiment, biological and technical replicates were conducted
for each condition. Temozolomide (TMZ, Sigma-Aldrich, St.
Louis, MO, United States) and DMSO 2% were used as positive
and negative control, respectively.
Inhibition (%) =
Mean No. of untreated cells (DMSO control)−
Mean No. of treated cells
Mean No. of untreated cells (DMSO control)
× 100 (1)
The cytotoxicity of the top compound was evaluated on
multiple GBM cell lines, 1321N1, LN229, Snb19, and HEK293T
(immortal cells) human embryonic kidney and normal brain cells
MEF. Ten micromolar concentration of the top compound was
used to treat the cells followed by trypan blue exclusion assay
to quantify the percentage of live and dead cells. The inhibition
percentage was calculated as described above.
Inhibitory Kinetic Study
The inhibitory kinetic study was performed for 24 h exposure
time using different concentrations 100, 75, 50, 25, 10 µM of
the top compound on 1321N1, Snb19, and LN229 cells. After
treatment, the cells were collected as described in the cytotoxicity
assay. The positive control TMZ was also utilized. After that
the dose-response curves were plotted. Half maximal inhibitory
concentration (IC50) was calculated based on the curves fit. The
two cell lines with best IC50 were selected for further time-
dependent study. In this study, the cells were treated with IC50
concentration of the top compound and incubated for 48 and
72 h. The time-dependent graph was plotted.
Illumina Sequencing and Bioinformatics
Analysis
To perform the RNA-seq, RNA of samples had to be isolated.
LN229 and Snb19 cells were seeded into 6 well-plate and
incubated overnight. The cells were treated with THTMP
and TMZ for 24 h at IC50 concentration. The total RNA
of the cells were isolated using GeneJET RNA Purification
Kit (Thermo Fisher Scientific) following the manufacture’s
instructions. Then, the total RNA of 18 samples of LN229
and Snb19 cells (including triplicates of THTMP treated, TMZ
treated and untreated samples) were sent to whole transcriptome
sequencing by Biomedicum Functional Genomics Unit (FuGU,
University of Helsinki, Finland) using Illumina NextSeq 500. The
sequencing produced data in bcl format which was converted into
FASTQ file format.
RNASeq Data Analysis Pipeline
FastQC (Andrews, 2010) (version 0.11.2) was used for quality
control to ensure that the quality value was above Q30. The
Human (homo sapiens) genome FASTA file1 and gene annotation
1ftp://ftp.ensembl.org/pub/release-92/fasta/homo_sapiens/dna/
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GTF file (Homo sapiens human release 922) were obtained
from Ensembl. Although RNA-seq is a popular research tool,
there is no gold standard for analyzing RNA-seq data. Among
the available tools, we chose up-to-date open source tools for
mapping, retrieving read counts, and differential expression
analysis. We used STAR (Dobin et al., 2013) (version 2.6) to
generate indexes and to map reads to the human genome.
For assembly, we chose SAMtools (Li et al., 2009) (version
1.2) and the “union” mode of HTSeq (Anders et al., 2014)
(version 0.9.1), as the gene-level read counts could provide
more flexibility in the differential expression analysis. Both
STAR and HTSeq analyses were conducted using the high-
performance research computing resources provided by TUT
TCSC Merope computing cluster3 in the Linux operating system
(version 2.6.32). Differential expression (DE) and statistical
analysis were performed using DESeq2 (Love et al., 2014) (release
3.3) in R (version 3.2.4). DESeq2 was chosen as a leading
statistical method4. DESeq2 internally corrects for library size,
so it is important to provide un-normalized raw read counts as
input. We used variance stabilizing transformation to account
for differences in sequencing depth. P-values were adjusted
for multiple testing using the Benjamini-Hochberg procedure
(Benjamini and Hochberg, 1995). A false discovery rate adjusted
p-value (i.e., q-value) <0.05 was set for the selection of DE genes.
Gene Ontology (GO) and Pathway
Analysis
Gene ontology (Ashburner et al., 2000) and KEGG pathway
(Kanehisa and Goto, 2000) analyses were performed with the
PANTHER over-representation Test (released on Feb 03, 2018)
in PANTHER version 13.15 (Mi et al., 2009; Emmert-Streib
and Glazko, 2011). This program supports the human genome.
PANTHER uses a binomial test and a Bonferroni correction for
multiple testing and displayes z-scores to indicate whether a
potential regulator is activated or inhibited. We used the default
settings for statistical analysis in both the PANTHER pathway
and GO terms. In the analyses, only pathways and GO terms with
p-value <0.05 and fold change of 1.5 were set as cutoff values.
Analysis of Cell Cycle Progression
The Snb19 and LN229 cells were cultured in 96-well plates
with the initial density of 1 × 105 cells/well. Cells were
incubated overnight with appropriate culture conditions. When
the cell confluence reached 60%, they were treated with the IC50
concentration of the top compound for 8 h. Then Premo FUCCI
Cell Cycle Sensor ∗BacMam 2.0∗ (Thermo Fisher Scientific)
was added into each well and incubated for 16 h following
the manufacture’s protocol. The cells were then captured using
confocal microscope. The analysis of images was done based on
different fluorescent colors of the cells in which red fluorescent
cells were the cells in G1 phase, green fluorescent cells means the
2ftp://ftp.ensembl.org/pub/release-92/gtf/homo_sapiens
3https://wiki.eduuni.fi/display/tutsgn/TUT+Narvi+Cluster
4https://bioconductor.org/packages/release/bioc/vignettes/DESeq2/inst/doc/
DESeq2.html
5http://www.pantherdb.org/, released on October 24, 2016
cells in S, G2, M phase and the overlaid red and green fluorescent
cells are the cells in G1/S phase (Zielke and Edgar, 2015).
Annexin V-FITC/PI Apoptotic Assay
To determine the apoptosis and/or necrosis of the top compound
on Snb19 and LN229 cell lines, the Dead Cell Apoptosis Kit with
Annexin V FITC and PI (Thermo Fisher Scientific) was used.
The apoptosis determination was performed followed by the
standard protocol from the manufacture. Briefly, the cells were
cultured in 6 well-plate with the initial density of 5 × 105 cells/
well. The cells were treated with IC50 concentration of the top
compound, TMZ and negative control (DMSO) were harvested
and washed in cold PBS. The cell pellets were then resuspended
in 1× annexin-binding buffer provided in the kit. Then, 5 µL
of FITC conjugated Annexin V and 1 µL of the 100 µg/mL PI
working solutions were added to the 100 µL of cell suspension.
The cells were incubated at room temperature for 15 min prior to
the fluorescence measurements. The image acquisition was done
by using EVOS imaging system (Thermo Fisher Scientific) with
20× objective magnification.
Detection of Intracellular Reactive
Oxygen Species
The Snb19 and LN229 cells were cultured in 12-well plates with
the initial density of 1 × 105 cells/well. Cells were incubated
overnight with appropriate culture conditions then treated with
the IC50 concentration of the top compound and TMZ for 5 h.
After that, cells were harvested by centrifugation at 3000 rpm
for 10 min and transferred into 96-well plate. Cells were
incubated with 2 µM 2′,7′-dichlorodihydrofluorescein diacetate
(H2DCFDA), known as dichlorofluorescin diacetate (Sigma-
Aldrich, St. Louis, MO, United States), for 30 min at cell culture
conditions. The cells were then washed with pre-warm PBS and
recovered in pre-warmed completed medium for 20 min prior the
fluorescence measurement. Fluorescence intensity was measured
using plate reader (Fluoroskan Ascent FL, Thermo Labsystems)
at excitation 485 nm and emission 538 nm. DMSO and hydrogen
peroxide 200 µM were used as the negative and positive controls.
The fold increase in ROS production was calculated using the
following formula (2).
Fold increase = Ftest − Fblank
Fcontrol − Fblank (2)
Where: Ftest is the fluorescence readings from the treated wells,
Fcontrol is the fluorescence readings from the untreated wells, and
Fblank is the fluorescence readings from the unstained wells.
Caspases 3/7 Activities Assay
Snb19 and LN229 cells were seeded on 96 well-plates at the
initial density of 1 × 104 cells/well with appropriate medium.
After culturing for 24 h, cells were treated with TMZ and the
top compound at IC50 concentration for 5 h. Determination
of caspase activity was performed using Caspase-Glo 3/7 Assay
kit (Promega, Madison United States) followed by the standard
protocol from the manufacture. Briefly, the plate containing cells
were removed from incubator and allowed to equilibrate to room
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temperature for 30 min. An amount of 100 µl of Caspase-Glo
reagent was added to the plate containing 100 µl of treated
cell, untreated cell, blank or TMZ. After that, content of wells
was gently mixed using a plate shaker at 300–500 rpm for 30 s.
The plate was incubated for further 1 h before measuring the
luminescence using a plate-reading luminometer (Fluoroskan
Ascent FL, Thermo Labsystems). The fold increase in caspase 3/7
was calculated using formula (2) as described in ROS assay.
Statistical Analysis
All of the experiments were conducted with three biological
repeats and technical repeats. The data was analyzed using
SPSS 20.0. For comparison between the tested groups, statistical
significant differences were evaluated with the t-test using a
threshold of P < 0.001 and P < 0.05. For comparison of more
than two groups, statistical significance was determined with a
one-way ANOVA test with the level of significance at p< 0.05.
RESULTS
Characterization of Human Glioma Cells
Treated With Alkylaminophenols
Three GBM cell lines were treated with 100 µM HNPMI,
THMPP, and THTMP (Figure 1A). After 24 h of treatment,
the cells lost the proliferative activity with dramatic changes
in morphology, losing attachment property and incrementing
granularity (Figure 1B). Delightfully, THTMP strongly inhibited
the growth of GBM cells 1321N1, LN229, and Snb19 (Figure 1C).
At 100 µM, THTMP was responsible for almost 100% cell
death of 1321N1 and LN229 and approximately 80% cell
death of Snb19. HNPMI also showed high cytotoxicity on
LN229 and Snb19 with more than 80% cell death while it
had little effect on 1321N1 with only 23% cell death. THMPP
has the least cytotoxicity effect compared to THTMP and
HNPMI (Figure 1C).
From the above results, it is concluded that THTMP is a
potent inhibitor of GBM cell growth. Here, we also used an
immortal cell line, HEK293T and a non-tumorous cell line, MEF
to examine the effect of THTMP. In general, THTMP has higher
cytotoxicity effect on GBM cells compared with immortal and
non-tumorous cells. In which, approximately 3 to 12% cell death
were found in different GBM cell lines whilst only 2 and 1%
growth inhibition were observed in HEK293T and MEF cells,
respectively (Figure 1D). Thus, this result suggests that THTMP
has the selectivity on GBM cells and was hence selected for
further studies.
The dose-dependent inhibitory effect of THTMP against GBM
cells was studied at 10, 25, 50, 75 and 100 µM concentrations
(Figure 1E). Among three cell lines, LN229 was the most affected
by THTMP with an IC50 concentration of 26.5 ± 0.03 µM,
followed by 1321N1 with an IC50 of 61.9 ± 0.65 µM and least
inhibited cell line was Snb19 with an IC50 of 75.5± 2.18. Besides,
TMZ showed better effect on Snb19 than LN229 while seemly no
effect was observed in 1321N1. This is in an agreement with the
previous findings (Lee, 2016).
Based on the results obtained for THTMP and TMZ in dose
response curve, further studies were performed on LN229 and
Snb19 to understand the compound action mode as anticancer
drug. To observe the effect of THTMP over the hours on cell
viability, LN229 and Snb19 cells were treated for 24, 48, and 72 h
with IC50 concentration (Figure 1F). The result showed that there
was a time-dependent effect on Snb19 from 24 to 72 h and on
LN229 from 24 to 48 h. In details, the growth inhibition of Snb19
was increased from 32.2 to 36.5% and to 43.1% at 24, 48, and 72 h
post-treatment, respectively. The growth inhibition of LN229 was
increased from 29.4% at 24 h treatment to 33.4% at 48 h treatment
and was decreased to 13.7% at 72 h treatment.
Global Change in Gene Expression in
Response to Top Compound
Principal Component Analysis (PCA) and Hierarchical
Clustering Analysis
We performed PCA at each sample to determine whether samples
in each cell line group clustered with each other or other groups.
First, we used HTSeq to count reads that uniquely aligned to one
gene, and these data were then imported into DESeq2 to generate
PCA plots (Figure 2A). Furthermore, PCA scree plots confirmed
that principal components 1 (PC1) and 2 (PC2) accounted for
70–80% of the total variation in gene expression at each time
point (Figure 2B). To further investigate the cell-type dependent
nature of the DEGs, we performed hierarchical clustering of the
top 100 DEGs (i.e., those with the smallest q-values identified
in the cell line analysis in DESeq2). In agreement with the PCA
plots, this analysis demonstrated clustering of almost all sample
groups from each cell line forming two clusters (Figure 2D).
Differentially Expressed Genes (DEGs)
In average, 20,090 genes were mapped by at least one read in
each of the two cell line samples. Overall, 7,299 DEGs with
a q-value <0.05 and fold change >1.5 (LN229 1,550; Snb19
5,749) were detected over the two comparisons (C1: THTMP
vs. Untreated; C2: THTMP vs. TMZ) in the cell type analysis
of DESeq2 (Supplementary Tables S1–S4). The results of plot
analysis of gene expression in two cell lines of the GBM after
treatment are shown in Figure 2C. The numbers of differentially
expressed genes with more than 1.5-fold change were higher in
Snb19 than in LN229 (Figure 3D). Indeed, there were higher
number of differentially expressed genes in these Snb19 cell line
when compared with LN229 cell line as shown in Figure 2C.
We applied the MA plot function in DESeq2 to visualize the top
genes with the smallest q-values (Figure 3A). We investigated
the similarity in differential gene expression profiles regulated
LN229 and Snb19. The fold-changes in overlapped genes filtered
by the q-value<0.05 were plotted for LN229 and Snb19 cell lines.
Comparison of gene expression profiles showed correlations
between LN229 and Snb19 cell lines (R2 > 0.10, Figure 3C
left in C1; R2 > 0.12, Figure 3C right in C2). Venn diagrams
indicated overlap in genes whose expression was regulated in the
same direction (Figure 3B). We identified 3,714 DEGs between
THTMP and untreated (negative control) samples among the
cell lines (q-value <0.05) (Supplementary Tables S1–S4 and
Figure 3B top). In this comparison, Snb19 demonstrated the
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FIGURE 1 | Effect of alkylaminophenols characterized by cell growth arrest. (A) Molecular structure of three tested phenolic compounds (HNPMI, THMPP, and
THTMP). (B) Demonstrated images of morphological changes in GBM cells at 24 h after treatment. (C) Cell growth inhibition was determined with trypan blue
solution for compounds HNPMI, THMPP, THTMP, and TMZ against GBM cells (1321N1, LN229, and Snb19) at 100 µM concentration. (D) Growth inhibitory effect of
THTMP on different cell lines 1321N1, LN229, and Snb19 and HEK293T cells at 10 and 100 µM at 24 h post-treatment. (E) Effect of THTMP and TMZ on GBM cell
growth. Different concentrations including 10, 25, 50, 75, and 100 µM were utilized and incubated for 24 h. (F) Time-dependent effect of THTMP and TMZ on
LN229 and Snb19 at 24, 48, and 72 h post-treatment at IC50 concentrations. All experiments were performed with three biological repeats and two technical
repeats. ∗∗P < 0.001, ∗P < 0.05 compared to the TMZ.
most DEGs, with 321 of the 3,714 DEGs common to both
LN229 and Snb19. We also compared the THTMP and TMZ
samples as a positive control group, both individually and
combined as a single “affected” group. In these comparisons,
3,585 number of DEGs were identified, with the largest number
of DEGs identified in Snb19 cell line, and 289 out of 3,585 DEGs
common in both cell lines (Supplementary Tables S1–S4 and
Figure 3B down).
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FIGURE 2 | Hierarchical clustering analysis, heatmap, and principal component analysis. (A) Principal component analysis (PCA) for all samples measured from
LN229 and Snb19 cell lines. Principal component 1 (PC1) and principal component 2 (PC2) were identified by variance stabilizing transformation in DESeq2 on cell
line samples. (Red, Untreated samples; Green, Temozolomide samples; Blue, THTMP samples). (B) The figure shows the percentage of variance that indicates how
much variance was explained by PC1 and PC2. (C) Scatter plot analysis of gene expression using comparisons (THTMP vs. Untreated and THTMP vs. TMZ) in
LN229 and Snb19 cell lines from the GMB. Genes whose expression levels changed by more than 1.5-fold after treatment are indicated in red. (D) Hierarchical
clustering analysis and heatmap of the 100 genes with the smallest q-values in the time course analysis in DESeq2 (for Untreated, Temozolomide, and THTMP
designate three replicate samples; negative, positive, and compound are individual cell lines in each group).
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FIGURE 3 | DEGs comparisons on LN229 and Snb19 samples. (A) MA-plot from means and log fold changes. The figure shows differential gene expression from
the two inter-group comparisons (THTMP vs. Untreated; THTMP vs. Temozolomide). For MA-plot construction, a gene was considered to be differentially expressed
between groups at an absolute log2 fold change >1.5 or<-1.5 and a q-value of 0.05 (moderated t-test; Benjamini-Hochberg procedure). (B) Overlapping DEGs in
LN229 and Snb19 samples compared with positive and negative control at C1 and C2. For each comparison, only genes with a q-value <0.05 were considered as
DEGs. The number of DEGs found at each comparison are indicated. (C) Scatter plots of fold-changes in gene expression levels after treatment of C1 and C2. The
R2 value was calculated for genes with t-test p-values <0.1. (D) The total number and upregulated/downregulated number of DEGs of both cell lines after treatment.
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A substantial overlap of DEGs was present when comparing
LN229 and Snb19 samples with the control group at C1 and
C2. The overlapping DEGs between the cell line were higher
at C1 (3,714 DEGs) than at C2 (3,585 DEGs), supporting the
two groups behave similarly at the end-stage of the treatment, as
expected based on Figure 3B. Both cell lines shared appreciable
proportions of gene expression profiles (21.23% of genes in
LN229; 78.76% of genes in Snb19). The complete lists of DEGs
from the cell line analysis and all pairs of comparisons appear in
Supplementary Tables S1–S4.
Dynamic Cellular Damage Responses
Induced by THTMP
The gene ontology was conducted to analyze up and down
regulated genes regarded to DNA damage. GO analysis
identified the list of genes that were enriched in DNA
replication, sister chromatid segregation, DNA-dependent DNA
replication, chromosome segregation, sister chromatid cohesion,
and nuclear chromosome segregation process. These biological
processes are involved in the DNA replication pathway in
both cell lines when they were treated with THTMP and
TMZ (Figure 4A). Enrichment analysis for GO molecular
function and pathways clearly demonstrated related phenotypes
associated with GBM (Figures 4B,C). GO terms cadherin
binding, damaged DNA binding for molecular function appeared
to be significantly overrepresented, and none significantly
underrepresented. Cadherin binding, a type I membrane
protein involved in cell adhesion and damaged DNA binding,
interacting selectively and non-covalently with damaged DNA
have coordinated effect on regulation and function in DNA
damage (Daido et al., 2005). Previous studies have shown that
GBMs are highly resistant to single inhibitor, suggesting that
combinational strategies involving standard chemotherapies like
TMZ and pathway inhibitors might be a possible future direction
for treating GBM (Jacinto and Esteller, 2007).
Genes associated with the DNA damage were listed in the
Figure 4D. In general, more DEGs were observed in Snb19 when
they were treated with THTMP and TMZ. Here, the top 20
DEGs were listed in Figure 4D. In LN229, eight DEGs were
expressed when they were treated with THTMP and six DEGs
were found in TMZ treatment. CDK1 gene is downregulated
when the cells were treated with THTMP and TMZ in both cell
types. It is reported that CDK1 was observed to be enriched in the
p53 signaling pathway, which is induced by a number of stress
signals, including DNA damage, oxidative stress and activated
oncogenes. It is noted that p53 signaling network is an integral
tumor suppressor pathway in GBM pathogenesis that affects
cellular processes, including cell cycle control and cell death
execution (Stegh et al., 2010). Moreover, CDKN1A was found to
be upregulated in Snb19 when they were treated with THTMP
(Figure 4D). It is noted that CDKN1A is a gene encoding for p21
protein which contributes to the cell response to DNA damage
not only by inactivating G1-phase cyclins/CDKs complexes,
but also through other processes, which possibly include direct
interaction with PCNA to inhibit DNA replication, and indirect
effects mediated by interaction with other cell cycle regulators.
Thereby, our result suggests that DNA damage has been
confirmed by the downregulation of CDK1 as well as
upregulation of CDKN1A leading to activation of p53 and
p21 signaling; thus, inhibiting the growth of glioblastoma.
Moreover, CDK1 also plays an important role in cell cycle
control (Santamaría et al., 2007). Here, the downregulation of
CDK1 expression was identified in THTMP treated conditions
confirming cyclin-dependent kinase mediated cell cycle arrest.
Detailed investigation of cell cycle arrest was performed using
biosensor and gene expression profiling.
THTMP Induces G1/S DNA
Damage Checkpoint
It has been demonstrated that DNA damage induced the cell
cycle arrest in proliferating mammalian cells (Erasimus et al.,
2016). At first, cell cycle progression was imaged using FUCCI
fluorescent biosensor and microscopy. Different phases of the cell
cycle were determined based on different fluorescence signals, red
signal corresponding to G1 phase, yellow signal corresponding
to G1/S phase and green signal corresponding to S/G2/M phase
(Figure 5A). In this study, similar results were observed in both
cell lines after the treatment. In DMSO condition, the highest
number of cells were present in S/G2/M phase, moderate number
of the cells were present in G1 phase, and least number of the
cells were present in G1/S phase. Upon THTMP treatment, the
majority of the cells were presence in G1 phase, following is the
G1/S phase and small number of cells were in S/G2/M phase. In
TMZ condition, the percentage of cells in different phases varied
between G1/S and S/G2/M phase. According to these results, it is
to conclude that GBM cells were arrested at G1/S phase when they
were treated with THTMP and were arrested at S/G2/M phase
when they were under TMZ treatment (Figure 5B).
Here, we show that THTMP induced the downregulation of
many genes related to DNA replication, thereby, inhibiting the
process of DNA replication and cell cycle progression. Next,
genes associated with cell cycle progression were selectively
analyzed (Figure 5C). There are several biological processes
involved in cell cycle pathway that have been activated by the
treatment. It includes cell cycle G1/S phase, G1/S transition
of mitotic cell cycle, G2/M transition of mitotic cell cycle,
cell cycle G2/M phase transition, cell cycle checkpoint and
positive regulation of cell cycle (Figure 4A). Regarding the
expression of various genes involved in cell cycle, genes in
Snb19 have higher fold change compared to those in LN229
(Figure 5C). For example, the fold change of CCNA2 gene is
−0.4 and −2.5 in LN229 and Snb19, respectively, when they
were treated with THTMP. The fold change of CCNB2 gene is
−0.3 and−2.1 in LN229 and Snb19, respectively, when they were
treated with TMZ.
Here, the genes associated with G1 phase and G1/S checkpoint
were first selectively analyzed (Figure 5C). CCNA2 gene coding
to cyclin A2 protein was found to be downregulated in both
cell lines when they were treated with THTMP. In Snb19, genes
CCNE1 and CCNE2 coding to Cyclin E1 and E2 proteins were
found to be decreased in THTMP treatment. It is noted that
overexpression of Cyclin A and Cyclin E has the function to
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FIGURE 4 | Selected results of Gene Ontology terms and pathways over-representation analysis (FDR < 0.01) on the top 20 terms. (A) Overrepresented Gene
Ontology (GO) Biological process terms. (B) Overrepresented GO Molecular function terms. (C) Overrepresented KEGG pathway terms. The x-axis contains the
number of genes involved in a particular pathway that were found differentially expressed in our study. The pie charts indicate the fraction of the signature genes
associated with significantly enriched terms. The number of genes were normalized to allow comparisons between groups within the same cell line, and the vertical
line on the pathways corresponds to the significant p-values. (D) The top 20 DEGs which are involved in the DNA damage on LN229 and Snb19. The DEGs were
color coded, with the colors corresponding to the up- and down- expressed.
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FIGURE 5 | Cell cycle analysis using FUCCI and RNA-seq. (A) Demonstrated images of cell which were dyed with FUCCI in different conditions (DMSO, TMZ, and
THTMP). Red cells corresponding to the cells in G1, yellow cells corresponding to the cells in G1/S phase and the green cells corresponding to the cells in S/G2/M
phase (B) Percentage of total cell in different phases when they were treated with THTMP and TMZ. (C) The top 20 DEGs which are involved in the cell cycle on
LN229 and Snb19. The DEGs were color coded, with the colors corresponding to the up- and down- expressed.
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regulate G1/S transition when they complex with CDK2; thus,
decreased expression level of CCNA2, CCNE1, and CCNE2 could
lead to mediate the G1/S arrest. Moreover, BUB1 was identified
to be downregulated in this study and was enriched in biological
processes associated with the mitotic cell cycle, including cell
cycle chromatid segregation, G1/S transition of mitotic cells and
DNA replication. CDC20 appears to act as a regulator protein
interacting with several other proteins at multiple points in the
cell cycle. We found that CDC20 gene was downregulated and
enriched in cell cycle and oocyte meiosis pathways.
In case of TMZ treatment, FUCCI analysis shows that
both Snb19 and LN229 cells were arrested at S/G2/M phase.
It is in accordance with our gene expression analysis. Genes
CCNB1, CCNB2, CCNA2, which relate to Cyclin B1 and
Cyclin A2, were found to be decreased. These two cyclins have
the function to regulate G2/M transition when they complex
with CDK1. Moreover, CDKN1A (p21) and GADD45A, two
downstream target genes of p53 in the G2 checkpoint, were
found to be increased in LN229 and Snb19, respectively, at
the transcriptional level. Previous studies have reported that
increased p21 expression led to the repression of cyclin B1
and Cdc2 promoters and that increased GADD45A expression
inhibits Cdc2 activity, thereby mediating G2/M arrest (Jin et al.,
2000; Yang et al., 2000).
The results show that THTMP induced cell cycle arrest at
G1/S phase while TMZ induced cell cycle arrest at G2/M phase
in both cell lines. This result implies that THTMP has inhibited
synthesis of GBM cells before they can entry to replication and
division periods; therefore, strongly preventing cell proliferation.
Moreover, G1/S phase arrest of cell cycle progression provides
an opportunity for cells to either undergo repair mechanisms or
follow the apoptotic pathway (Bartek and Lukas, 2001).
THTMP Increases ROS Production and
Induces Pro-apoptotic and
Anti-apoptotic Genes
Apoptosis induction assay was performed using Annexin V/PI
double staining. Here, the percentage of apoptosis was calculated
based on the cells with Annexin V-FITC positive and PI negative
and both Annexin V-FITC and PI positive. The percentage of
necrosis was defined based on the cells with Annexin V-FITC
negative and PI positive (Chen et al., 2008). Figure 6A shows
the live, apoptosis and necrosis of LN229 and Snb19 when
they were treated with THTMP and TMZ. Generally, apoptosis
induction was observed in both cell lines compared with positive
control and untreated conditions. The apoptosis percentage of
LN229 cells treated with THTMP is 45.8% while only 21.9 and
11.2% were obtained when they were treated with TMZ and
DMSO, respectively. In case of Snb19 cells, 56.4% of apoptotic
cells were found in THTMP treated condition whilst TMZ and
untreated conditions exhibit only 36.2 and 11.5% apoptotic cells.
Beside the apoptotic cells, necrotic cells were also observed in
both cell lines. However, necrosis percentage is less than 10%
in case of Snb19 while in LN229, 27.0 and 7.6% were found
to be necrotic cells when they were treated with TMZ and
THTMP, respectively.
The results above are in accordance with the gene expression
profile showing the enrichment of apoptosis pathways including
neuron apoptotic process, positive regulation of neuron apoptotic
process, regulation of apoptotic signaling pathway, regulation of
neuron apoptotic process, intrinsic apoptotic signaling pathway
and extrinsic apoptotic signaling pathway. Genes involved in
regulation of apoptotic process were presented in Figure 6B.
Moreover, the gene expression profile indicates lower number
of the DEGs related to apoptosis process in TMZ treatment
compared to THTMP treatment (Figure 6B). The expression
changes showing in Figure 6B revealed that THTMP tended to
induce pro-apoptotic genes, reduce anti-apoptotic genes and also
induce some anti-apoptotic genes.
Among pro-apoptotic genes, CTNNB1 gene coding for
β-catenin protein was downregulated in LN229 cells when
they were treated with THTMP. It is reported that abnormal
accumulation of β-catenin contributes to most cancers and
repressed CTNNB1 also leads to inducing apoptosis in some
tumor cells (Yang et al., 2017). Interestingly, the pro-apoptotic
Bcl-2 family gene MAGED1 was also found to be upregulated in
LN229 whereas BBC3 (PUMA) gene was upregulated in Snb19
when they were treated with THTMP. Moreover, BCL2L12, an
anti-apoptotic gene, was found to be downregulated in Snb19
cells. It is noted that BCL2L12 expression is upregulated in most
human glioblastomas. Expression of Bcl2L12 results in resistance
to apoptosis (Yang et al., 2015). Our findings demonstrated that
THTMP has shown the ability to induce apoptosis of Snb19 and
LN229 via mitochondrial pathway throughout the upregulation
of pro-apoptotic and downregulation of anti-apoptotic Bcl-
2 family genes.
Although the altered expression of genes described above
could confirm apoptosis, genes involved in anti-apoptosis were
expressed when the cells were treated with THTMP. The anti-
apoptotic characteristics of Snb19 cells were identified by the
downregulation of several genes from the membrane stress
receptors, such as TNFSF10, TNFSF12, and TNFRSF2. Moreover,
the upregulation of RELA, a member of NFkB family, suggested
a decline in inflammatory processes and strong anti-apoptotic
properties for this cell line. In LN229 cells, the regulation of the
TNF receptor pathway as well as NFkB signaling pathway was
not significantly affected, but there was a modest upregulation
of BIRC6 encoded for BIRC protein, a member of the inhibitor
of apoptosis (IAP) gene family preventing apoptotic cell death.
Interestingly, the BIRC5 was suppressed in Snb19.
In addition to the activation of apoptotic pathways in the
treated cells, reactive oxygen species (ROS) could lead to cell
cycle arrest and induces apoptosis in anticancer treatment (Circu
and Aw, 2010). It is well known that ROS is produced in
both normal and abnormal cells especially in cancer cells. ROS
plays an important role in proliferation, survival, metastasis and
angiogenesis (Clerkin et al., 2008). In this study, the effects of
THTMP, TMZ and H2O2, a positive control in the levels of
ROS on GBM cells, was assessed using ROS production assay.
Figure 6C shows an increase of ROS level when the cells were
treated with THTMP and TMZ. Interestingly, the fold increase of
ROS of Snb19 and LN229 cells treated with THTMP were higher
than H2O2. As seen in Figure 6C, Snb19 cells have higher level of
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FIGURE 6 | Apoptosis induction determination using double stains Annexin V and Propidium iodide and RNA-seq. (A) Percentage of apoptosis, necrosis and live
cell using Dead Cell Apoptosis Kit with Annexin V-FITC and PI of untreated cell (DMSO control TMZ and compound THTMP at 24 h post-treatment on Snb19 and
LN229. (B) The top 20 DEGs which are involved in apoptosis of LN229 and Snb19. The DEGs were color coded, with the colors corresponding to the up- and
down- expressed. (C) Effect of THTMP and TMZ in intracellular ROS production. Fluorescence intensity of ROS was determined by activity of 2 µM H2DCFDA
(30 min), fluorescent probe. H2O2 was used as the positive control. (D) Activity of caspases 3/7 in LN229 and Snb19. Caspase 3/7 was determined using
luminescence plate reader. Fold increase in ROS and caspases 3 and 7 activity of LN229 and Snb19 cell lines was calculated when they were treated with THTMP
and PC at IC50 concentration. Triplicates were performed for each condition.
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ROS compared to LN229 in all of the conditions. In which, up to
2 fold increase was found in THTMP treatment of Snb19 while
only 1.3 fold increase was observed in LN229. The same trend
was observed for the TMZ treatment in which 1.5 fold and 1.2
fold were obtained in Snb19 and LN229, respectively. Thus, ROS
were significantly produced when GBM cells were affected with
THTMP. This suggests that higher ROS level could be interlinked
with the observed apoptotic cell death of cancer cells upon
treatment with compound THTMP. Moreover, in mammalian
cells, ROS are produced by normal oxidative metabolism and
cellular antioxidants such as superoxide dismutase (SOD1) and
thioredoxin (TRX1) detoxify these species (Covarrubias et al.,
2008). A study indicated that decreasing SOD1 and TRX1 could
lead to apoptosis induction in glioma cells when they were treated
with kaempferol, a natural phenolic compound, via elevation of
ROS (Sharma et al., 2007). In agreement, we also found out that
while THTMP treatment had no effect on TRX1, a decrease in
SOD1 was observed in Snb19 cells (Supplementary Table S3).
Thus, THTMP induced ROS-mediated apoptosis.
According to Figure 6D, caspase 3/7 was not significantly
increased in both cell lines when they were treated with THTMP
and TMZ. This is also in agreement with the gene expression
profile where we could not find the significant expression of
CASP3 and CASP7 in LN229 cells (Figure 6B). In case of
Snb19 cells, although the CASP3 and CASP7 were expressed,
the CASP3 was downregulated and CASP7 was upregulated
when they were treated with THTMP (Figure 6B). This result
interprets the no change in caspase 3/7 activation assay results
(Figure 6C). The repression of caspase genes might be caused
from the activation of anti-apoptotic genes (Stegh et al., 2008).
Thus, apoptosis inductions of GBM cells by THTMP and TMZ
were not via caspase 3/7. Instead of CASP3 and CASP7, CASP4
was found to be upregulated in Snb19 when they were treated
with both THTMP and TMZ. Therefore, the result implies the
involvement of caspase 4 in Snb19 when they were treated with
THTMP and TMZ.
DISCUSSION
DNA damage response induced by THTMP was validated and
shown to be dose-and time-dependent. A detailed analysis of
global molecular expression profiling is required in order to
understand the complex cellular responses. Here, by combining
biochemical studies with high-throughput RNA sequencing,
the changes in gene expression in glioma cells induced by
THTMP was explored. Our results show that genes involves in
DNA damage, DNA replication, cell cycle arrest and apoptosis
induction were transcriptionally modulated and highly enriched
when GBM cells were treated with THTMP.
Firstly, our study demonstrated a THTMP induced activation
of various genes associated with DNA damage and cell cycle
arrest. The cell cycle arrest in GBM when they were treated
with THTMP and TMZ may be explained by transcriptional
expression change of some crucial genes that are listed in
Figure 5B. CCNA2 gene was found in both Snb19 and LN229
when they were treated with THTMP compound. This gene
belongs to a highly conserved cyclin family and the encoded
protein of this gene is crucial in the control of the cell cycle at
G1/S and G2/M transition points. Here, several important genes
in control cell cycle at G1/2 and G2/M such as CCNA2, BUB1,
CDC20 are selected for further discussion in order to understand
their mechanism in controlling cell cycle of GBM.
In previous studies, it is reported that overexpression of
CCNA2 is involved in tumor transformation and progression
in numerous types of cancer (Uhlen et al., 2010). As expected,
our results show that CCNA2 was downregulated, which is in
accordance with the function of cyclin A2 protein in cell cycle
indicating that CCNA2 inhibits the growth of GBM. BUB1
was also found to be downregulated that can explain the G1/S
transition arrest since the BUB family of genes encode proteins
that are involved in large multi-protein kinetochore complex, and
are reported to be key component of the checkpoint regulator
pathway. BUB1 encodes a serine/threonine protein kinase which
plays an important role in mitosis (Tang et al., 2006), and
BUB1 accumulates at unattached kinetochores where it mediates
the recruitment of mitotic arrest deficient (Mad) dimers.
Combination of Mad and BUB1 leads to prevention of premature
separation of sister chromatids until all chromosomes are
correctly attached to kinetochores; thus, correctly chromosome
segregation achieved (Ricke et al., 2011). This suggests that GBM
cell growth may be inhibited by regulating the mitotic cell cycle
in THTMP treated conditions (Grabsch et al., 2003). In addition,
previous reports indicate that CDC20 is highly expressed in
various type of human tumors including breast, cervical and
glioblastoma cancer (Marucci et al., 2008; Jiang et al., 2011;
Rajkumar et al., 2011). It is also reported that expression level
of CDC20 is correlated with the grade of glioblastoma and it is
expressed at different levels in patients at different ages (Bie et al.,
2011). In the study CDC20 was downregulated, which leads to
conclude that CDC20 may inhibit GBM growth. According to
the biological process enrichment results, CCNA2 was enriched
in cell cycle and oocyte meiosis pathways, in which CDK1, BUB1
and CDC20 were also involved. These genes are also known as
key genes playing a crucial role in promoting GBM growth (Chen
et al., 2016). Repression of these genes when the cells were treated
with THTMP indicates that this compound strongly inhibits the
growth of GBM throughout cell cycle arrest.
Secondly, we detected apoptotic effects induced by THTMP.
Analysis of apoptosis genes subsequently revealed that the
progress of apoptosis was accompanied by changes in both pro-
apoptotic and anti-apoptotic gene expression, consistent with the
observation in other chemotherapeutic therapies in cancer cells
(Kim et al., 2003). It is noted that BCL2L12 is overexpressed
in primary GBM and functions to inhibit post-mitochondrial
apoptosis signaling (Stegh et al., 2007). This study shows that
THTMP has induced apoptosis via mitochondrial pathway in
both LN229 and Snb19 cell lines due to the suppression of Bcl-
2 family, BCL2L12. The study also shows that a large number
of genes of Snb19 was expressed compared to LN229 when they
were treated with THTMP. The anti-apoptotic genes expressed
in LN229 and Snb19 are different. This result implies that
apoptosis pathways of GBM cells will be executed in different
mechanisms when they were treated with THTMP. This study
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shows that TMZ also induced apoptosis in GBM cells as explored
by Annexin V/PI double staining; however, the gene profile of
this condition is still limited. Here, the absence of caspase 3/7
activation indicates that THTMP has not induced apoptosis via
caspase 3 and 7 of LN229 and Snb19, but the caspase 4 might be
involved in the apoptosis pathway of Snb19 cells.
CONCLUSION
Overall, the effect of THTMP on GBM cells is relatively
much stronger than TMZ in all aspects. This study provides
experimental evidence that THTMP is capable of inhibiting the
growth of GBM cells. THTMP has the ability to induce DNA
damage through the p53 signaling pathway leading to cell cycle
arrest. The G1/S checkpoint arrest depends on the decrease of
cyclin A2 in both Snb19 and LN229 cells-treated with THTMP.
Moreover, the decrease of cyclin E1 and E2 in Snb19 in THTMP
treatment also contributes to the G1/S checkpoint arrest. This
result suggests that THTMP facilitates cancer cells to undergo
programmed cell death pathways, apoptosis in glioblastoma
cells. The induction of apoptosis of GBM in THTMP treated
conditions is associated with increasing pro-apoptotic factor of
Bcl-2. In addition, it is indicated that caspase 4 may play a role in
this apoptosis induction instead of caspase 3/7.
The findings on inhibition of GBM proliferation and
downregulation of cell cycle genes in the G1/S phase not only
provide a better understanding of the mechanisms of THTMP, a
phenolic compound, as anticancer agent, but also open an avenue
for investigating the role of oxidative stress in GBM involving
cell cycle and apoptosis regulation. However, testing THTMP
on glioma animal model and computational pharmacogenomics
approaches (Musa et al., 2018) will allow this compound to be
used as a potential chemotherapeutic drug for glioma treatment.
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